Studies in breast cancer, melanoma, colon cancer, lung cancer and almost all solid malignancies that spread to lymph nodes have confirmed that metastatic cells move in an orderly manner from the ...

Navidea Biopharmaceuticals announced results from two Phase 3 clinical trials of Lymphoseek (technetium 99m tilmanocept) Injection in patients with melanoma of the skin, assessing the performance of ...

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its completed Phase 3 Lymphoseek ...

“The Lymphoseek NDA marks a significant clinical and regulatory milestone for our novel, receptor-targeted radiopharmaceutical agent, Lymphoseek, that has undergone extensive clinical evaluation over ...

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it received a Complete Response Letter (CRL) ...

Please provide your email address to receive an email when new articles are posted on . Intraoperative pathology assessment led to increased use of both axillary lymph node dissection and axillary ...

The intraoperative molecular tests (RD‑100i OSNA system and Metasin test) are used during breast cancer surgery to detect the presence of 1 or 2 biological markers that are associated with metastatic ...